Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
Leadership Companies Business Strategies

Novartis Appoints AbbVie Immunology Leader Horber To Succeed Tschudin

  • News

Executive Summary

President of Innovative Medicines International and chief commercial officer Marie-France Tschudin will leave Novartis after nearly seven years.

You may also be interested in...



Quick Listen: Scrip's Five Must-Know Things

In this week's podcast edition of Five Must-Know Things: the rise of Novo Nordisk; senior level changes at Novartis; Moderna’s progress against BA.2.86; major new CNS drugs coming; and Boehringer Ingelheim’s head of innovation on R&D priorities.

Novartis On Its ‘US First’ Commercial Plan

US Innovative Medicines president Victor Bulto talked to Scrip about why the company is pivoting to a commercial strategy that prioritizes the US and what that means for developing and selling drugs.

Novartis To Cut 8,000 Jobs In Global Restructure

CEO Vas Narasimhan wants the company to be more agile and identify more blockbuster opportunities.

Table

View full table

Related Content

Scrip

Topics

Related Companies

Tags:
Leadership Companies Business Strategies
Latest Headlines

Glenmark Divests API Company, Setting Out On Distinct Journeys

Infographic: A Snapshot Of Non-Alcoholic Steatohepatitis R&D

A Look Into The Future Of NASH

Travere Hopes For FDA Full Approval Despite Filspari Trial Endpoint Miss

See All
UsernamePublicRestriction

Register

SC149004

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By